EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY 4.0

The Swedish national guidelines on prostate cancer: recurrent, metastatic and castration resistant disease

Johan Stranne, Elin Axen, Ola Bratt, Stefan Carlsson, Jon Kindblom, Kimia Kohestani, Anna Kristiansen, Ingela Franck Lissbrant, Gabriel Moise, Elinor Nemlander, David Robinsson, Christian Torbrand und 4 weitere

Scandinavian Journal of Urology · 21.04.2026 · 61 · 138-147

DOI: 10.2340/sju.v61.45715 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Scandinavian Journal of Urology, online erschienen am 21.04.2026. Verfasst von Johan Stranne und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Göteborg, Sweden; Department of Urology, Sahlgrenska Univer…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Neoplasm Recurrence, Local, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This article presents a summary of the 2025 Swedish prostate cancer guidelines, focusing on recurrence after local treatment, metastatic disease, and castration-resistant prostate cancer.

Results

The 2025 Swedish guidelines introduce several important updates. Prostate specific membrane antigen (PSMA)-PET/CT is recommended only when PSA exceeds 0.2 µg/L, and reporting should follow the defined PSMA-RADS-scale. PSMA-PET/CT is preferred over lymph-node dissection for staging. A strong recommendation is issued for radiotherapy to the primary tumour in all oligometastatic men with a life expectancy > 5 years, whereas metastasis-directed therapy is restricted to clinical trials. Systemic treatment pathways now prioritise androgen receptor pathway inhibitors (ARPI) plus androgen deprivation therapy (ADT), with triple therapy (including docetaxel) used more selectively. Pathway-specific staging algorithms have been revised. The oly (ADP-ribose) polymerase inhibitor (PARPi) section has expanded, with broader genomic-based selection and integration into treatment sequencing. Two new chapters and an appendix address cardiovascular risk assessment before ARPI or chemotherapy. Supportive care is substantially strengthened.Compared with the EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer 2025, the Swedish guidelines 2025 applies PSMA-PET/CT more conservatively, restricts PSMA-guided nodal salvage therapy, and issues a more universal recommendation for local radiotherapy in oligometastatic disease. The Swedish guidelines 2025 prioritise ARPI + ADT and limit triple therapy and PARPi combinations due to regulatory and reimbursement constraints. PARPi are largely reserved for BRCA1/2-mutated disease. The Swedish guidelines 2025 provide a more comprehensive framework for rehabilitation and survivorship.

Conclusions

The 2025 Swedish prostate cancer guidelines introduce multiple new recommendations and differ in several aspects from the European guidelines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsNeoplasm Recurrence, LocalProstatic Neoplasms, Castration-ResistantMaleHumansSwedenNeoplasm MetastasisNeoplasm StagingAndrogen AntagonistsPositron Emission Tomography Computed Tomography

Substanzen

Androgen Antagonists

Autor:innen und Institutionen

  • Department of Urology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Göteborg, Sweden; Department of Urology, Sahlgrenska University Hospital, Göteborg, Sweden. johan.stranne@gu.se.
  • Department of Urology, Sahlgrenska University Hospital, Göteborg, Sweden.
  • Department of Urology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Göteborg, Sweden; Department of Urology, Sahlgrenska University Hospital, Göteborg, Sweden.
  • Section of Urology, Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden.
  • Department of Oncology, Sahlgrenska University Hospital, Göteborg, Sweden.
  • Department of Pelvic Cancer, Karolinska University Hospital, Stockholm, Sweden.

Zitieren

APA

Stranne, J., Axen, E., Bratt, O., Carlsson, S., Kindblom, J., Kohestani, K., Kristiansen, A., Franck Lissbrant, I., Moise, G., Nemlander, E., Robinsson, D., Torbrand, C., Trägårdh, E., Wallström, J., Wennerberg, C., & Thellenberg Karlsson, C. (2026). The Swedish national guidelines on prostate cancer: recurrent, metastatic and castration resistant disease. Scandinavian Journal of Urology, 61, 138-147. https://doi.org/10.2340/sju.v61.45715

Vancouver

Stranne J, Axen E, Bratt O, Carlsson S, Kindblom J, Kohestani K, et al. The Swedish national guidelines on prostate cancer: recurrent, metastatic and castration resistant disease. Scandinavian Journal of Urology. 2026;61:138-147. doi:10.2340/sju.v61.45715

BibTeX
@article{Stranne2026,
  author = {Stranne, Johan and Axen, Elin and Bratt, Ola and Carlsson, Stefan and Kindblom, Jon and Kohestani, Kimia and Kristiansen, Anna and Franck Lissbrant, Ingela and Moise, Gabriel and Nemlander, Elinor and Robinsson, David and Torbrand, Christian and Trägårdh, Elin and Wallström, Jonas and Wennerberg, Camilla and Thellenberg Karlsson, Camilla},
  title = {The Swedish national guidelines on prostate cancer: recurrent, metastatic and castration resistant disease},
  journal = {Scandinavian Journal of Urology},
  year = {2026},
  volume = {61},
  pages = {138--147},
  doi = {10.2340/sju.v61.45715}
}
Kostenlos starten →